Lenalidomide Faran (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4A9 E3 ubiquitin ligase complex, altering its substrate specificity. This triggers degradation of transcription factors such as Ikaros and Aiolos, leading to reduced tumor cell proliferation, inhibition of new blood‑vessel formation, and enhanced immune‑mediated tumor cell killing.

The specific dose of Lenalidomide Faran is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosing regimens are individualized and should follow the prescriber’s instructions and any local regulatory guidelines.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of known teratogenic risk. It should not be used by breastfeeding mothers, and effective contraception is required for both male and female patients of reproductive potential during treatment and for a defined period after discontinuation.

To order Lenalidomide Faran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide is more potent, has a shorter half‑life, and generally exhibits a more favorable safety profile, especially regarding peripheral neuropathy. Lenalidomide also shows stronger anti‑angiogenic activity and is the preferred option for the approved indications listed above.

Store Lenalidomide Faran at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and avoid exposure to excessive heat or humidity to maintain product stability.

Lenalidomide Faran is taken orally as a tablet. It may be swallowed with or without food, according to the prescriber’s guidance. Patients should follow the dosing schedule provided by their healthcare professional and not alter the timing or frequency without medical advice.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and the potential development of secondary malignancies like acute myeloid leukemia. Patients should be monitored closely for these complications throughout therapy.

Lenalidomide Faran should not be used by pregnant women or by anyone who cannot adhere to strict contraceptive measures. Patients with uncontrolled severe renal impairment, active uncontrolled infections, or a history of hypersensitivity to lenalidomide should avoid the medication unless a specialist determines that benefits outweigh risks.